["Ecstasy"-induced psychotic depersonalization syndrome].
The 'designer drug' 3,4-methylenedioxy-metamphetamine (MDMA; 'Ecstasy'), which has become increasingly popular in the past few years, is supposed to induce a feeling of euphoria with amphetamine-like stimulant effects. It was for some time considered harmless, but neurotoxic effects on serotonergic neurons are now well documented. To supplement case reports on different drug-induced psychopathological and somatic complications published in recent literature, the case of a 21-year-old female patient is reported, who exhibited a protracted psychotic depersonalization disorder with suicidal tendency after the first intake of two tablets of "ecstasy". In the course of six months the symptoms remitted only gradually despite administration of a serotonin re-uptake inhibitor, 'flash-backs' occurring repeatedly.
Wodarz
N
N
Psychiatrische Klinik und Poliklinik, Universität Würzburg.
Böning
J
J
D015104:3,4-Methylenedioxyamphetamine / Q000009:adverse effects / Q000031:analogs & derivatives*; D000328:Adult; D003131:Combined Modality Therapy; D003861:Depersonalization / Q000139:chemically induced* / Q000188:drug therapy / Q000523:psychology; D015198:Designer Drugs / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D016666:Fluvoxamine / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008140:Lorazepam / Q000008:administration & dosage / Q000009:adverse effects; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D011605:Psychoses, Substance-Induced / Q000188:drug therapy / Q000523:psychology*; D013405:Suicide / Q000523:psychology; D000092864:Suicide Prevention
D015198:Designer Drugs; D015104:3,4-Methylenedioxyamphetamine; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D008140:Lorazepam; D016666:Fluvoxamine
"Ecstasy"-induziertes psychotisches Depersonalisationssyndrom.